Disease relevance of NRG3

• In this study we examined using immunohistochemical staining expression of NRG1alpha, NRG1beta, NRG2alpha, NRG2beta, NRG3 and NRG4 in sixty cases of pre-invasive ductal carcinoma in situ of the breast representing different degrees of differentiation [1].
• Recombinant NRG-3 altered the growth of human breast cancer cells growing in vitro [2].
• The EGF-like domain of NRG-3 was generated as a recombinant protein in E. coli and used to test the specificity of receptor binding [2].

High impact information on NRG3

• Despite stimulating similar levels of gross receptor tyrosine phosphorylation, the EGF-like growth factors betacellulin, neuregulin-1beta, neuregulin-2beta, and neuregulin-3 exhibited different biological potencies in a cellular growth assay [3].
• However, the biological relevance of NRG2 and NRG3 remains elusive [4].
• Here, we report the identification of a new isoform of NRG3 that is specifically expressed in the human embryonic central nervous system [4].
• Neuregulin-2 and neuregulin-3 were expressed by MMC only, while neuregulin-1, amphiregulin and transforming growth factor-alpha were expressed by both MMC and normal plasma-cells [5].
• Characterization of a neural-specific splicing form of the human neuregulin 3 gene involved in oligodendrocyte survival [4].

Anatomical context of NRG3

• These results indicate that NRG-3 is a potential regulator of normal and malignant breast epithelial cells in vivo [2].
• NRG-3 was expressed in cell lines derived from breast cancer [2].

Associations of NRG3 with chemical compounds

• We also show that recombinant neuregulin 3 acts as an oligodendrocyte survival factor by activating the phosphoinositide 3-kinase signalling pathway [4].

Other interactions of NRG3

• High levels of expression of NRG2beta and NRG4 were associated with high-grade tumours (p</=0.005), NRG2beta staining was associated with tumour size >25 mm (p=0.005) while NRG3 nuclear staining was present more often in low-grade tumours (p=0.039) [1].

References